Table of Contents Author Guidelines Submit a Manuscript
Advances in Virology
Volume 2015 (2015), Article ID 972067, 9 pages
http://dx.doi.org/10.1155/2015/972067
Research Article

Evaluating Andrographolide as a Potent Inhibitor of NS3-4A Protease and Its Drug-Resistant Mutants Using In Silico Approaches

Department of Biotechnology, Siddaganga Institute of Technology, Tumkur, Karnataka 572 103, India

Received 4 May 2015; Accepted 30 August 2015

Academic Editor: Jay C. Brown

Copyright © 2015 Vivek Chandramohan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Lavanchy, “Evolving epidemiology of hepatitis C virus,” Clinical Microbiology and Infection, vol. 17, no. 2, pp. 107–115, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. M. S. Sulkowski, D. F. Gardiner, M. Rodriguez-Torres et al., “Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection,” The New England Journal of Medicine, vol. 370, no. 3, pp. 211–221, 2014. View at Publisher · View at Google Scholar
  3. B. Helbling, W. Jochum, I. Stamenic et al., “HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon α-2a and ribavirin,” Journal of Viral Hepatitis, vol. 13, no. 11, pp. 762–769, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Voigt, C. Schulz, G. Klausen et al., “Pegylated interferon α-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients,” Journal of Infection, vol. 53, no. 1, pp. 36–42, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Padmanabhan, U. Garaigorta, and N. M. Dixit, “Emergent properties of the interferon-signalling network may underlie the success of hepatitis C treatment,” Nature Communications, vol. 5, article 3872, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. C. N. Hayes, M. Imamura, H. Aikata, and K. Chayama, “Genetics of IL28B and HCV-response to infection and treatment,” Nature Reviews Gastroenterology and Hepatology, vol. 9, no. 7, pp. 406–417, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Kau, J. Vermehren, and C. Sarrazin, “Treatment predictors of a sustained virologic response in hepatitis B and C,” Journal of Hepatology, vol. 49, no. 4, pp. 634–651, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Asselah and P. Marcellin, “New direct-acting antivirals' combination for the treatment of chronic hepatitis C,” Liver International, vol. 31, supplement 1, pp. 68–77, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Sarrazin and S. Zeuzem, “Resistance to direct antiviral agents in patients with hepatitis C virus infection,” Gastroenterology, vol. 138, no. 2, pp. 447–462, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Manabe, I. Fuke, O. Tanishita et al., “Production of nonstructural proteins of hepatitis C virus requires a putative viral protease encoded by NS3,” Virology, vol. 198, no. 1, pp. 636–644, 1994. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Murayama, L. Weng, T. Date et al., “RNA polymerase activity and specific RNA structure are required for efficient HCV replication in cultured cells,” PLoS Pathogens, vol. 6, no. 4, Article ID e1000885, 2010. View at Google Scholar · View at Scopus
  12. L. Tomei, C. Failla, E. Santolini, R. De Francesco, and N. La Monica, “NS3 is a serine protease required for processing of hepatitis C virus polyprotein,” Journal of Virology, vol. 67, no. 7, pp. 4017–4026, 1993. View at Google Scholar · View at Scopus
  13. J. J. Kiser, J. R. Burton, P. L. Anderson, and G. T. Everson, “Review and management of drug interactions with boceprevir and telaprevir,” Hepatology, vol. 55, no. 5, pp. 1620–1628, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. B. L. Pearlman, “Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care,” The Lancet Infectious Diseases, vol. 12, no. 9, pp. 717–728, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. D. I. Soumana, A. Ali, and C. A. Schiffer, “Structural analysis of asunaprevir resistance in HCV NS3/4A protease,” ACS Chemical Biology, vol. 9, no. 11, pp. 2485–2490, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. S. M. K. Rates, “Plants as source of drugs,” Toxicon, vol. 39, no. 5, pp. 603–613, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. K. J. Halazun, A. Aldoori, H. Z. Malik et al., “Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases,” European Journal of Surgical Oncology, vol. 34, no. 1, pp. 55–60, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. S. S. Handa and A. Sharma, “Hepatoprotective activity of andrographolide from Andrographis paniculata against carbontetrachloride,” Indian Journal of Medical Research, vol. 92, pp. 276–283, 1990. View at Google Scholar · View at Scopus
  19. S. P. Thyagarajan, S. Jayaram, V. Gopalakrishnan, R. Hari, P. Jeyakumar, and M. S. Sripathi, “Herbal medicines for liver diseases in India,” Journal of Gastroenterology and Hepatology, vol. 17, supplement 3, pp. S370–S376, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. S. K. Tewari, A. Niranjan, and A. Lehri, “Variations in yield, quality, and antioxidant potential of Kalmegh (Andrographis paniculata nees) with soil alkalinity and season,” Journal of Herbs, Spices and Medicinal Plants, vol. 16, no. 1, pp. 41–50, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. P. M. Scola, L.-Q. Sun, A. X. Wang et al., “The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection,” Journal of Medicinal Chemistry, vol. 57, no. 5, pp. 1730–1752, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Hwang, S. Thangapandian, and K. W. Lee, “Molecular dynamics simulations of sonic hedgehog-receptor and inhibitor complexes and their applications for potential anticancer agent discovery,” PLoS ONE, vol. 8, no. 7, Article ID e68271, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Jayakanthan, G. Wadhwa, T. M. Mohan, L. Arul, P. Balasubramanian, and D. Sundar, “Computer-aided drug design for cancer-causing H-Ras p21 mutant protein,” Letters in Drug Design & Discovery, vol. 6, no. 1, pp. 14–20, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. A.-P. Hynninen and M. F. Crowley, “New faster CHARMM molecular dynamics engine,” Journal of Computational Chemistry, vol. 35, no. 5, pp. 406–413, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. A. A. Ezat, N. S. El-Bialy, H. I. A. Mostafa, and M. A. Ibrahim, “Molecular docking investigation of the binding interactions of macrocyclic inhibitors with HCV NS3 protease and its mutants (R155K, D168A and A156V),” The Protein Journal, vol. 33, no. 1, pp. 32–47, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Wingen, J. S. Schwed, K. Isensee et al., “Benzylpiperidine variations on histamine H3 receptor ligands for improved drug-likeness,” Bioorganic and Medicinal Chemistry Letters, vol. 24, no. 10, pp. 2236–2239, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Wu, D. H. Robertson, C. L. Brooks, and M. Vieth, “Detailed analysis of grid-based molecular docking: a case study of CDOCKER—a CHARMm-based MD docking algorithm,” Journal of Computational Chemistry, vol. 24, no. 13, pp. 1549–1562, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. C. A. Lipinski, “Lead- and drug-like compounds: the rule-of-five revolution,” Drug Discovery Today: Technologies, vol. 1, no. 4, pp. 337–341, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Hou, J. Wang, W. Zhang, and X. Xu, “ADME evaluation in drug discovery. 6. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules?” Journal of Chemical Information and Modeling, vol. 47, no. 2, pp. 460–463, 2007. View at Publisher · View at Google Scholar
  30. A. Asoodeh, L. Haghighi, J. Chamani, M. A. Ansari-Ogholbeyk, Z. Mojallal-Tabatabaei, and M. Lagzian, “Potential angiotensin I converting enzyme inhibitory peptides from gluten hydrolysate: biochemical characterization and molecular docking study,” Journal of Cereal Science, vol. 60, no. 1, pp. 92–98, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Dammalli, V. Chandramohan, M. I. Biradar, N. Nagaraju, and B. S. Gangadharappa, “In silico analysis and identification of novel inhibitor for new H1N1 swine influenza virus,” Asian Pacific Journal of Tropical Disease, vol. 4, no. 2, pp. S635–S640, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. H. R. Naika, V. Krishna, K. Lingaraju et al., “Molecular docking and dynamic studies of bioactive compounds from Naravelia zeylanica (L.) DC against glycogen synthase kinase-3β protein,” Journal of Taibah University for Science, vol. 9, no. 1, pp. 41–49, 2015. View at Publisher · View at Google Scholar
  33. R.-R. Wang, Y.-D. Gao, C.-H. Ma et al., “Mangiferin, an anti-HIV-1 agent targeting protease and effective against resistant strains,” Molecules, vol. 16, no. 5, pp. 4264–4277, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. S.-Y. Lu, Y.-J. Jiang, J. Lv, T.-X. Wu, Q.-S. Yu, and W.-L. Zhu, “Molecular docking and molecular dynamics simulation studies of GPR40 receptor-agonist interactions,” Journal of Molecular Graphics and Modelling, vol. 28, no. 8, pp. 766–774, 2010. View at Publisher · View at Google Scholar · View at Scopus